Table 1.

Baseline and follow-up data of patients

Patient	Present age (years)	Sex	Duration of diabetes	Diabetic medication at baseline	Frequencya	Weight (kg)			BMI (kg/m2)			HbA1c (%)
						B	P	Fb	B	P	Fb	B	P
1	72	Male	6 years	Sitagliptin (50 mg) + metformin (1000 mg)	0–0–1	74.5	63.4	58	27.4	23.3	21.3	5.8	5
2	42	Female	1 year	Glimepiride 500 mg	1–0–0	77.1	57.6	56.3	30.1	22.5	22	7.7	5.1
3	68	Male	4 years	Repaglinide 0.5 mg Glimepiride (2 mg) + metformin (500 mg) + voglibose (0.2 mg)	1–0–0 0.5–0–0.5	72.2	65.4	65.2	23.9	21.6	21.6	8.5	6.2
4	52	Male	12 years	Metformin 500 mg	0–0.5–1	86.1	72	74.9	30.3	26.1	26.4	6.9	5.7

B=at baseline, BMI=body mass index, HbA1c, glycated hemoglobin, P=post-1 year of intervention. ^aThe dosage and timing of the medication (morning–afternoon–night). ^bFollow-up data as of December 2021